Image pharmaphorum Editor Views & Analysis Specialty pharma’s next big opportunity: it’s time for patie... In January 2020, the financial conglomerate Visa Views & Analysis What makes a good (and bad) pharmaceutical forecast model Forecasting is essential in providing clarity on decision making about the future, but poor-quality forecasts can result in decisions which are commercially damaging to organisations. Oncology Sponsored Meeting MSL training needs in an evolving landscape As medical treatments become more complex, the role of the Medical Science Liaison (MSL) has never been more important. Patients Deep Dive: Patients and Partnerships 2022 The concept of patient centricity has been a key talking point across the healthcare ecosystem for years. Load more results
Views & Analysis Specialty pharma’s next big opportunity: it’s time for patie... In January 2020, the financial conglomerate Visa
Views & Analysis What makes a good (and bad) pharmaceutical forecast model Forecasting is essential in providing clarity on decision making about the future, but poor-quality forecasts can result in decisions which are commercially damaging to organisations.
Oncology Sponsored Meeting MSL training needs in an evolving landscape As medical treatments become more complex, the role of the Medical Science Liaison (MSL) has never been more important.
Patients Deep Dive: Patients and Partnerships 2022 The concept of patient centricity has been a key talking point across the healthcare ecosystem for years.
News FDA probing cancer cases with Bluebird's CALD gene therapy The FDA is scrutinising reports of haematological cancers in patients treated with bluebird bio's Skysona gene therapy for neurological disease CALD
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
